Table 6.

Baseline characteristics and treatment effects between Group 2 and VIBRANT 52weeks trial (detailed version).

	Group 3 (first Bevacizumab and then Aflibercept or all Aflibercept) n = 15	VIBRANT 52weeks trial N = 91
Average amount of IVI	3.73 (1.58)	9.0 (1.8)	P < .0001*
Portion of patients with improvement < 5 ETDRS letters (%)	2	4	P = .27†
Portion of patients with improvement 5–9 ETDRS letters (%)	1	7
Portion of patients with improvement 10–14 ETDRS letters (%)	1	21
Portion of patients with improvement 15–29 ETDRS letters (%)	10	39
Portion of patients with improvement ≧ 30 ETDRS letters (%)	7	13
Portion of patients with ETDRS letters loss < 5ETDRS letters (%)	0	2
Portion of patients with ETDRS letters loss 5~9ETDRS letters (%)	1	2
Portion of patients with ETDRS letters loss 10~14ETDRS letters (%)	0	1
Portion of patients with ETDRS letters loss ≧ 15 ETDRS letters (%)	0	2

^*Two sample t test.

^†Fisher exact test.

IVI = intravitreal injection.